Biofrontera Launches Advanced Red Light Therapy for Skin Conditions

Introduction to RhodoLED XL

Biofrontera Inc., a biopharmaceutical company, has introduced RhodoLED XL, its new FDA-approved red light emitting LED lamp. This innovative device is designed to facilitate photodynamic therapy (PDT) and offers several advanced features to improve patient care.

Enhanced Design and Features

The RhodoLED XL lamp represents a significant upgrade in PDT technology with its state-of-the-art engineering, robust construction, and intuitive user interface. It is designed to be easy to maneuver and can accommodate various patient treatment positions, making the therapy process smoother for both practitioners and patients.

One of the critical features of the RhodoLED XL is its ability to illuminate a larger area during treatment. Unlike Biofrontera’s previous lamp, which had a single panel, the RhodoLED XL uses five panels. This enlargement allows for more comprehensive treatment in a single session, optimizing the effectiveness of PDT.

Compatibility with FDA-Approved Medications

The RhodoLED XL is specifically approved to be used in conjunction with Biofrontera’s PDT drug, Ameluz®. This drug is designed to treat conditions like actinic keratoses, which are pre-cancerous skin lesions. Having a larger illumination area means that a broader skin area can be treated at once, providing more effective therapy solutions.

Market Introduction and Adoption

Biofrontera has already begun distributing the RhodoLED XL to practitioners across the United States. In its first week, the company successfully shipped three units, garnering positive feedback from dermatology organizations.

Dr. Hermann Luebbert, CEO of Biofrontera Inc., expressed enthusiasm about the launch, stating that the new device underscores the company's commitment to innovation and excellence in dermatological treatments. The advanced features and user-friendly design of the RhodoLED XL are expected to set new standards in PDT.

User Feedback and Customer Experience

Cleaver Dermatology was the first to integrate the RhodoLED XL lamp into their practice. Dr. David Cleaver highlighted the advanced features and versatility of the device as significant improvements over previous models, enabling them to offer superior patient care.

Dr. Cleaver also praised Biofrontera's customer service, noting the team's dedication to ensuring a smooth integration of the new technology into their practice.

Forward-Looking Statements

While Biofrontera is optimistic about the future of the RhodoLED XL lamp, it acknowledges certain risks and uncertainties. Factors such as supply chain disruptions and changes in healthcare practices could impact the commercialization success of this new device.

About Biofrontera Inc.

Based in the United States, Biofrontera Inc. specializes in commercializing pharmaceutical products for dermatological conditions, particularly focusing on photodynamic therapy (PDT) and topical antibiotics. Their licensed products are widely used to treat pre-cancerous and bacterial skin conditions.

To learn more about Biofrontera and their products, you can visit their official website or follow them on social media platforms like LinkedIn and Twitter.

Contact Information

For more information about the RhodoLED XL lamp, you can reach out to Biofrontera's investor relations at ir@bfri.com or visit their contact page.

Biofrontera Inc. remains dedicated to advancing dermatological care through innovation, providing practitioners with the tools they need to offer effective treatments for their patients.